This company is engaged in the provision of scientific_research and development services for various therapies and treatment of gout and metabolic CAUSE_OF_DEATH. It was_incorporated in DATE. The company has a registered_head_office_located in CITY,_STATE_OR_PROVINCE, COUNTRY COUNTRY COUNTRY COUNTRY. The company is involved in the discovery and development of novel therapeutics for the treatment of type NUMBER CAUSE_OF_DEATH and related metabolic disorders. It conducts original_investigation undertaken_on a_systematic_basis to_gain new knowledge. The company 's product TITLE in its pipeline include MBX - 102, an oral, small - molecule insulin sensitizer DATE in Phase_NUMBER testing ; MBX - 8025, which is being evaluated in a Phase_NUMBER clinical_trial ; MBX - 2982, which is being evaluated in a Phase_NUMBER clinical_trial ; and MBX - 2044, DURATION_DURATION generation insulin sensitizer. The company aims_to transform the treatment of type NUMBER CAUSE_OF_DEATH and other metabolic disorders.